Table 1 Demographics, baseline data and comorbidities at time of diagnosis (mean (SD) or median and range)

n of patients

101

63

38

Age (years)

61.4 (13)

60.2 (14)

63.3 (11)

0.237

Male/female

40/61

27/36

13/25

0.389

Time from first symptoms to diagnosis (months)

5.0 (1–36)

5.0 (1–24)

6.0 (1–36)

0.822

Hemoglobin (g%)

8.4 (1.4)

8.1 (1.3)

8.8 (1.5)

0.017

Erythrocyte sedimentation rate (mm/h)

98 (5–138)

98 (5–138)

99 (14–136)

0.762

Serum albumin (g/l)

31.3 (5.4)

30.8 (5.3)

32.0 (5.6)

0.285

CRP (mg/l)

29 (1–221)

40 (2–221)

24 (1–152)

0.054

Urinary protein excretion (mg/day)

1456 (38–8474)

1259 (38–8474)

1843 (184–7344)

0.143

Serum creatinine (umol/l)

554 (84–1904)

573 (146–1904)

428 (84–1722)

0.060

HD requirement on admission (n, %)

56 (55%)

41 (65%)

15 (40%)

0.012

BVAS

21 (11–34)

24 (21–34)

15 (11–20)

<0.001

p-/c-ANCA positivity (n)*

57/36

33/29

24/7

0.024

Anti-MPO level in p-ANCA positive patients (IU/ml)

67 (6–100)

67 (6–100)

70 (11–100)

0.807

Anti-PR3 level in c-ANCA positive patients (IU/ml)

100 (32–100)

100 (50–100)

82 (32–100)

0.354

Dose of iv pulse MP** mg/kg/bw

11.7 (4.1)

12.7 (4.2)

10.1 (3.3)

0.002

Dose of iv bolus CYC*** mg/kg/bw

9.7 (1.6)

9.8 (1.6)

9.5 (1.6)

0.371

Cumulative dose of MP (mg)

11640 (3006–32334)

11238 (3006–32334)

12332 (5076–26364)

0.621

Follow-up time (days)

963 (30–3000)

843 (30–3000)

1393 (51–3000)

0.231

Organ involvement n (%)

 Renal

101 (100)

63 (100)

38 (100)

1.000

 Respiratory tract

43 (43)

38 (60)

5 (13)

<0.001

 Ear-throat-nose

39 (39)

33 (52)

6 (16)

<0.001

 Musculoskeletal

55 (55)

33 (52)

22 (58)

0.590

 Skin

16 (16)

9 (14)

7 (18)

0.581

 Eyes

5 (5)

4 (6)

1 (3)

0.648

 Gastrointestinal

9 (9)

9 (14)

0 (0)

0.013

 Nervous system

17 (17)

14 (22)

3 (8)

0.062

 Cardiovascular

5 (5)

5 (8)

0 (0)

0.154

Baseline comorbidities n (%)

963 (30–3000)

843 (30–3000)

1393 (51–3000)

0.231

 History of:

  Coronary artery disease

11 (11)

9 (14)

2 (5)

0.201

  Congestive heart failure

5 (5)

4 (6)

1 (3)

0.648

  Peripheral vascular dis.

1 (1)

1 (2)

0 (0)

1.000

  Cerebrovascular disease

11 (11)

7 (11)

4 (11)

1.000

  Chronic pulmonary dis.

16 (16)

9 (14)

7 (18)

0.581

  Peptic ulcer disease

8 (8)

6 (10)

2 (5)

0.707

  Liver disease

5 (5)

4 (6)

1 (3)

0.648

  Diabetes mellitus

8 (8)

3 (5)

5 (13)

0.149

  Malignancy

7 (7)

3 (5)

4 (11)

0.421

Number of patients with

  0

50

30

20

0.862

  1

30

19

11

  2 or more comorbidity scores

21

14

7